From the 1930s, polychlorinated biphenyls (PCBs) have been manufactured in large quantities for use in many industrial applications until they were banned in most countries in the 1970s. Dichlorodiphenyltrichloroethane (DDT) is a pesticide that since the 1940s has been used worldwide for malaria vector control, and it is still in use in some areas ([@r1]; [@r2]). PCBs and the main DDT metabolite dichlorodiphenyldichloroethylene (*p*,*p*´-DDE) bioaccumulate in fat tissues, biomagnify through the food chain, are highly persistent in living organisms, and comprise the bulk of organochlorine residues in human tissues ([@r40]). The concentrations of these chemicals in blood, fat, and milk have decreased over the past 30 years but are still detectable in blood of the general population all over the globe ([@r31]). It has been suggested that organochlorines may interfere with fetal growth through interaction with endogenous steroid hormone signaling ([@r14]; [@r41]). Birth weight restriction related to PCBs was first described in humans after the 1968 Yusho incident in Japan, where thousands of pregnant women were intoxicated by PCB-contaminated cooking rice oil ([@r75]). During the past 15 years, additional research has addressed human reproductive toxicity of PCBs in studies of fishing communities, fish eaters, and the general population in various regions, as reviewed by [@r63] and [@r40]. Findings from these studies on the relation between maternal PCB exposure and birth weight are not consistent---some indicating an inverse association ([@r15]; [@r33]; [@r45]; [@r50]; [@r56], [@r57], [@r55]; [@r74]), an inverse association among male infants only ([@r59]), a positive association ([@r10]), or no association at all ([@r17]; [@r20]; [@r38]; [@r43]; [@r66]).

A large U.S. study of women giving birth between 1959 and 1966 (when DDT was still being used) found a dose--response relationship between DDE concentration in maternal serum and low birth weight ([@r39]). Children in the high exposure group (\> 60 ng/g) weighed 150 g less and were born about 1 week earlier than the children in the low exposure group (\< 15 ng/g). Similar results were observed in an Indian study of pregnant women with high DDT exposures ([@r58]), but serum DDT and/or DDE was not associated with birth weight in two other studies ([@r17]; [@r74]).

Many factors may contribute to the discrepant findings in earlier observational studies of reproductive effects of PCBs. This includes correlations in some populations between persistent organochlorines (POCs) and such dietary nutrients as n-3 fatty acids that may increase gestational age ([@r20]), limited study size, insufficient exposure levels or contrasts between compared populations ([@r74]), exposure to different mixtures of PCB congeners ([@r45]), confounding by other organochlorines such as hexachlorobenzene (HCB) ([@r13]), and different susceptibility of studied populations ([@r59]). Publication bias could also be a problem, with studies not finding an association being underreported.

A recent review concluded that large-scale studies with a sufficient number of participants in well-defined groups with substantial exposure contrast are needed to further elucidate the possible adverse effects of POCs on human reproductive health ([@r63]). The ENRIECO (ENvironmental Health RIsks in European birth COhorts) framework of European birth cohorts and the cohorts included in the EU (European Union) OBELIX (OBesogenic Endocrine disrupting chemicals: LInking prenatal eXposure to the development of obesity later in life) project provide the basis for such a study.

The objective of this study was to examine associations between biological markers of exposure to POCs and birth weight in 12 European birth cohorts, including possible modifying effects of sex and tobacco smoking.

Methods
=======

*Description of the cohorts.* The ENRIECO project has provided an inventory of European birth cohorts that aim to investigate the impact of environmental exposures on health in pregnancy and early childhood. Among these cohorts, we identified 14 cohorts of pregnant women with individual measurements of PCB-153 and *p*,*p*´-DDE. One invited cohort declined participation for reasons not related to current hypotheses, and we excluded one cohort that used placenta tissue samples for exposure assessment \[the Finnish LUKAS cohort ([@r34])\]. Each cohort targeted the general population and included births from 1990 to 2008. We divided the INMA (INfancia y Medio Ambiente; Environment and Childhood) cohort into two populations based upon the matrix used for POC measurements (maternal serum or cord serum) and divided the INUENDO cohort into three populations (Greenland; Warsaw, Poland; and Kharkiv, Ukraine) resulting in 15 study populations with a total of 7,990 live-born singletons with PCB-153 measurements and 7,788 live-born singletons with *p*,*p*´-DDE measurements ([Table 1](#t1){ref-type="table"}). The concentrations of PCBs and *p*,*p*´-DDE were analyzed in maternal serum or whole blood collected during pregnancy (seven populations), cord serum or plasma (five populations), or breast milk (three populations). Detailed information regarding the study cohorts are provided in [Table 1](#t1){ref-type="table"} and Supplemental Material, [Table 1](#t1){ref-type="table"} (<http://dx.doi.org/10.1289/ehp.1103767>).

###### 

Description of the ENRIECO/OBELIX birth cohorts with biological PCB‑153/*p*,*p*´-DDE exposure biomarkers included in the present study.

  Cohort                                                           Setting location                             Time period          Enrollment method                                                                                                                                                                                           Only babies at term?   Other exclusion criteria                                                                                                                               Participation rate   Exposure assessment   Main reference                                                                                                                                                                                                       
  ---------------------------------------------------------------- -------------------------------------------- -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------- --------------------- ----------------------------------------------------------------------------------------------------------- ------------------------- ----------------------------------------------- -- ---------------- ------- -- --------------------------------------------
  GRD                                                              The Netherlands (Groningen--Rotterdam)       1990--1992           During prenatal consultations in late pregnancy by obstetricians or midwifes                                                                                                                                Yes                    Serious illness during pregnancy; congenital anomalies; white race; parity \> 2; cesarean section                                                      70%                                        Availability of biological samples                                                                          Cord plasma               At birth                                           382              ---        Huisman et al. 1995
                                                                   Germany (Düsseldorf)                         1993--1995           At delivery from the obstetrical wards of three Düsseldorf hospitals by three medical students                                                                                                              Yes                    Serious illness during pregnancy; congenital anomalies; native German families; parity \> 2; cesarean section                                          70%                                        Availability of biological samples                                                                          Cord serum                At birth                                           141              ---        Walkowiak et al. 2001
  FAROES2 (cohort 2)                                               Faroe Islands                                1994--1995           Consecutive births at the National Hospital in Torshavn, but from women living away from the capital area of Torshavn                                                                                       No                     Serious congenital disease                                                                                                                             64%                                        Availability of biological samples                                                                          Maternal serum            Week 34 (from antenatal consultation)              173              173        Steuerwald et al. 2000
  FAROES3 (cohort 3)                                               Faroe Islands                                1997--2000           Consecutive pregnant women                                                                                                                                                                                  No                     Serious congenital disease                                                                                                                             60%                                        Breast-feeding                                                                                              Breast milk               Days 3--5 and at 2 weeks                           596              596        Weihe et al. 2003
  INMA                                                             Spain (Menorca)                              1997--1999           During prenatal care at general practices of the island (in public or private health centers)                                                                                                               No                     Maternal age \< 16 years; to have followed any program of assisted reproduction; no wish to deliver in the reference hospital; speaking difficulties   98%                                        Availability of biological samples                                                                          Cord serum                At birth                                           404              405        Carrizo et al. 2006
                                                                   Spain (Granada)                              2000--2002           During hospital admission for delivery in the study area                                                                                                                                                    No                     Maternal age \< 16 years; to have followed any program of assisted reproduction; no wish to deliver in the reference hospital; speaking difficulties   Unknown                                    Availability of biological samples                                                                          Cord serum                At birth                                           ---              318        Ribas-Fito et al. 2006
                                                                   Spain (Valencia)                             2004--2005           During the first prenatal visit in the main public hospital or health center of the study area                                                                                                              No                     Maternal age \< 16 years; to have followed any program of assisted reproduction; no wish to deliver in the reference hospital; speaking difficulties   54%                                        Availability of biological samples                                                                          Cord serum                At birth                                           499              499        Vizcaino et al. 2010
                                                                   Spain (Sabadell)                             2004--2006           During the first prenatal visit in the main public hospital or health center of the study area                                                                                                              No                     Maternal age \< 16 years; to have followed any program of assisted reproduction; no wish to deliver in the reference hospital; speaking difficulties   60%                                        Availability of biological samples                                                                          Maternal serum            Week 13 of pregnancy                               605              605        Ribas-Fito et al. 2006
                                                                   Spain (Asturias)                             2004--2007           During the first prenatal visit in the main public hospital or health center of the study area                                                                                                              No                     Maternal age \< 16 years; to have followed any program of assisted reproduction; no wish to deliver in the reference hospital; speaking difficulties   45%                                        Availability of biological samples                                                                          Cord serum                At birth                                           25               25         Ribas-Fito et al. 2006
                                                                   Spain (Gipuzkoa)                             2006--2008           During the first prenatal visit in the main public hospital or health center of the study area                                                                                                              No                     Maternal age \< 16 years; to have followed any program of assisted reproduction; no wish to deliver in the reference hospital; speaking difficulties   68%                                        Availability of biological samples                                                                          Maternal and cord serum   Week 13.5 of pregnancy and at birth                604              605        Ribas-Fito et al. 2006
  DUISBURG                                                         Germany (Duisburg)                           2000--2002           Self-selected pregnant women within a predefined area mainly in Duisburg South                                                                                                                              Yes                    Nonhealthy mother--infant pairs; babies not from German- or Turkish-speaking families; Apgar score \< 8; parity \> 3                                   Unknown                                    Availability of biological samples                                                                          Maternal blood            32nd week of pregnancy                             189              189        Wilhelm et al. 2008; Wittsiepe et al. 2008
  *continued next page*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Table 1. continued.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Cohort                                                           Setting location                             Time period          Enrollment method                                                                                                                                                                                           Only babies at term?   Other exclusion criteria                                                                                                                               Participation rate                         Exposure assessment                                                                                                                                                                      Main reference              
                                                                   Selection criteria for exposure assessment                                                                                                                                                                                                                                                           *na*                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                   Biological matrix                            Time of collection                                                                                                                                                                                                               PCB-153                *p*,*p*´- DDE                                                                                                                                                                                                                                                                                                                                                                                                          
  FLEHSI                                                           Belgium (Flanders)                           2002--2004           At delivery in maternities of eight districts covering 20% of Flanders' area                                                                                                                                No                     Complications in delivery; living \< 5 years in the area; not Dutch reading                                                                            98%                                        Availability of biological samples                                                                          Cord plasma               At birth                                           1,068            1,114      Koppen et al. 2009
  INUENDO                                                          Greenland                                    2002--2004           By the local midwife when visiting the local hospital or health clinic from 15 municipalities of all regions in Greenland                                                                                   No                     Maternal age \< 18 years; not born in the country                                                                                                      90%                                        Availability of biological samples                                                                          Maternal serum            24 weeks on average                                546              546        Toft et al. 2005
                                                                   Poland (Warsaw)                              2003--2004           During antenatal classes at the obstetric outpatient clinic of the Gynaecological and Obstetric Hospital of the Warsaw School of Medicine or with physicians at a collaborating hospital in the same city   No                     Maternal age \< 18 years; not born in the country                                                                                                      68%                                        Availability of biological samples                                                                          Maternal serum            33 weeks on average                                199              199        Toft et al. 2005
                                                                   Ukraine (Kharkiv)                            2003--2004           During visit of one of eight antenatal clinics or three maternity hospitals in Kharkiv by gynecologists                                                                                                     No                     Maternal age \< 18 years; not born in the country                                                                                                      26%                                        Availability of biological samples                                                                          Maternal serum            24 weeks on average                                589              589        Toft et al. 2005
  Michalovce                                                       Slovakia                                     2002--2004           At delivery in maternities of two districts, one with high contamination of PCBs (Michalovce), and another one upwind and upstream of the chemical facility with lower contamination levels (Svidnik).      No                     Mothers with major illness; severe congenital anomalies; maternal age \< 18 years; living \< 5 years in the area; parity \> 4                          60%                                        Availability of biological samples                                                                          Cord serum                At birth                                           1,082            1,082      Hertz-Picciotto et al. 2003
  HUMIS                                                            Norway                                       2002--2006           2--4 weeks after birth during the routine health visit at home                                                                                                                                              No                     Non-fluent in Norwegian                                                                                                                                64%                                        Random selection in the cohort; breast-feeding                                                              Breast milk               Milk sampled on 8 consecutive days and pooled      418              418        Eggesbo et al. 2009
  PELAGIE                                                          France (Brittany)                            2002--2006           During first prenatal visit by gynecologists or obstetricians in the study area                                                                                                                             No                     Inclusion later than 19 weeks of pregnancy                                                                                                             80%                                        Stratified random selection of a subcohort among the live born cohort; availability of biological samples   Cord serum                At birth                                           396              395        Petit et al. 2010
  ELFE pilot                                                       France                                       2007                 At delivery in maternity department                                                                                                                                                                         No                     Maternal age \< 18 years; not French speaking; parity \> 2                                                                                             55%                                        Breast-feeding                                                                                              Breast milk               1 month after birth                                44               ---        Vandentorren et al. 2009
  RHEA                                                             Greece (Heraklion, Crete)                    2007--2008           Contact by interviewer of all pregnant women living in Heraklion around 12 weeks of gestation                                                                                                               No                     Maternal age \< 18 years; insufficient understanding of the Greek language                                                                             72%                                        Random selection of a small subcohort                                                                       Maternal serum            During the first interview                         30               30         Vardavas et al. 2010
  **a**Number of liveborn singleton births with exposure levels.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

*Exposure assessment.* Analysis of PCB-153 and *p,p*´-DDE. We used PCB-153 as a biomarker of PCB exposure because concentrations of this PCB congener are relatively high and highly correlated with the total molar concentration of PCBs ([@r18]; [@r44]; [@r46]). The elimination half-life of PCB-153 is \> 10 years ([@r54] and that of *p*,*p*´-DDE, the major metabolite of DDT, is approximately 5 years ([@r16]).

To facilitate comparisons of results from cohorts using different matrices for exposure assessment, we expressed all contaminant levels as wet weight cord serum levels, which directly reflect fetal exposure at the time of delivery (some compounds do not cross the placenta efficiently). For populations that did not have cord blood analyses, we estimated concentrations in cord serum from the concentrations measured in maternal serum (FAROES2, INMA, INUENDO, and RHEA), maternal whole blood (DUISBURG), or breast milk \[FAROES3, HUMIS (Norwegian Human Milk Study), and ELFE (Growing up in France) pilot\], using the following conversion factors \[for details, see Supplemental Material, pp. 2--3 (<http://dx.doi.org/10.1289/ehp.1103767>)\]:

Cord serum level (ng/L) = 0.20 × maternal serum level (ng/L)

Cord serum level (ng/L) = 1.20 × breast milk level (ng/g fat)

Cord serum level (ng/L) = 0.36 × maternal whole blood level (ng/L).

We compiled information about chemical-analytical methods and their detection limits \[see Supplemental Material, [Table 2](#t2){ref-type="table"} (<http://dx.doi.org/10.1289/ehp.1103767>)\]. High-quality analytical data were available for both PCB-153 and *p*,*p*´-DDE in each cohort except the GRD (Groningen--Rotterdam--Düsseldorf) and ELFE pilot cohorts, where only PCB-153 was measured. Spearman correlation coefficients between PCB-153 and *p*,*p*´-DDE in the cohorts ranged from 0.3 to almost 1, with a median of 0.6.

###### 

Concentration of PCB-153 and *p*,*p*´-DDE (ng/L) exposure biomarkers in cord serum, actual or obtained by conversion, of the ENRIECO/OBELIX birth cohorts.

  PCB-153 (ng/L)                                                                                                                                                                                                                                                                                                                            *p*,*p*´-DDE (ng/L)                                                                                                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- ------- -- --------------- -- ------- -- ------------- -- ------- -- ----------------- -- -------- -- ------------
  GRD*a*                                                                                                                                                                                                                                                                                                                                                          523        170.6 ± 99.7       150.0      0                ---        ---                  ---         ---
  FAROES2*b*                                                                                                                                                                                                                                                                                                                                                      167        648.4 ± 580.0      484.2      2 (1.2%)         167        1708.3 ± 1433.9      1208.0      0
  FAROES3*c*                                                                                                                                                                                                                                                                                                                                                      549        434.4 ± 347.6      345.6      0                549        987.7 ± 994.9        729.6       0
  INMA cord*a*                                                                                                                                                                                                                                                                                                                                                    1,227      156.1 ± 112.7      134.1      114 (9.3%)       1,515      1,380 ± 2269.8       596.0       57 (3.8%)
  INMA mat*b*                                                                                                                                                                                                                                                                                                                                                     856        52.8 ± 34.7        46.4       56 (6.5%)        857        262.6 ± 1030.0       131.2       5 (0.6%)
  DUISBURG*b*                                                                                                                                                                                                                                                                                                                                                     189        147.1 ± 99.4       124.0      0                189        323.7 ± 435.6        216.0       0
  FLEHSI*a*                                                                                                                                                                                                                                                                                                                                                       1,015      73.3 ± 56.7        60.0       202 (19.9%)      1,061      315.6 ± 344.6        220.0       19 (1.8%)
  Greenland*b*                                                                                                                                                                                                                                                                                                                                                    546        253.8 ± 341.9      155.1      7 (1.3%)         546        634.6 ± 684.2        435.7       10 (1.8%)
  Warsaw*b*                                                                                                                                                                                                                                                                                                                                                       199        23.8 ± 17.8        20.1       43 (21.6%)       199        824.7 ± 518.3        668.8       0
  Kharkiv*b*                                                                                                                                                                                                                                                                                                                                                      577        45.8 ± 36.3        37.1       20 (3.5%)        577        1100.8 ± 762.3       916.3       0
  Michalovce*a*                                                                                                                                                                                                                                                                                                                                                   1,036      393.5 ± 458.3      271.8      2 (0.2%)         1,036      1329.5 ± 1338.4      1014.7      8 (0.8%)
  HUMIS*c*                                                                                                                                                                                                                                                                                                                                                        409        43.1 ± 20.0        39.2       0                409        75.0 ± 111.0         49.8        0
  PELAGIE*a*                                                                                                                                                                                                                                                                                                                                                      396        126.1 ± 77.7       110.0      2 (0.5%)         395        253.3 ± 335.8        180.0       76 (19.2%)
  ELFE pilot*c*                                                                                                                                                                                                                                                                                                                                                   43         100.4 ± 52.7       92.5       0                ---        ---                  ---         ---
  RHEA*b*                                                                                                                                                                                                                                                                                                                                                         30         28.0 ± 13.4        23.8       0                30         573.2 ± 389.2        496.0       0
  Combined                                                                                                                                                                                                                                                                                                                                                        7,762      179.8 ± 156.6      139.6      448 (5.8%)       7,530      751.5 ± 819.1        527.9       175 (2.3%)
  mat, maternal serum. **a**Observed cord serum concentrations and **b**estimated cord serum concentrations based on measured concentrations in maternal serum (whole blood for DUISBURG) or **c**breast milk \[for additional information on conversions, see Supplemental Material, pp. 2--3 (http://dx.doi.org/10.1289/ehp.1103767)\].                                                                                                                               

*Outcome variable and covariates/confounders.* The outcome of interest was birth weight, which was extracted from medical records. Covariate data were obtained from questionnaires and medical record information for children and their mothers, including information from antenatal health care visits. Gestational age was estimated from the date of the last menstrual period and/or by ultrasound. For five study populations, the data obtained from the last menstrual period were replaced by ultrasound determination if the discrepancy between the two techniques exceeded 7--14 days \[see Supplemental Material, [Table 1](#t1){ref-type="table"} (<http://dx.doi.org/10.1289/ehp.1103767>)\]. All participants completed an extensive questionnaire themselves or by a telephone or face-to-face interview, assessing information on lifestyle, diet, use of tobacco and alcohol, residence history, health, education, hobbies, and occupation (if applicable). Each study was approved by appropriate national ethical committees, and mothers provided written informed consent for participation.

*Statistical analysis.* We developed a uniform script in SAS version 9.1 (SAS Institute Inc., Cary, NC, USA) and SPSS versions 17.0 and 18.0 (SPSS, Chicago, IL, USA) to define the variables, units, and categories used in statistical analyses for each of the 11 study centers. We allowed cohort specific variables for region and socioeconomic status. For some important confounders, missing values were replaced by the most frequent outcome for the study population. Specifically, missing data for smoking and alcohol consumption were replaced by nonsmoking/nondrinker, except for (in the INUENDO cohort) Greenland, where mothers with missing data for smoking were assumed to be smokers, and Warsaw, where mothers with missing data for alcohol were assumed to be moderate drinkers. For continuous variables (e.g., maternal height) missing values were replaced with the population-specific median.

In all 15 study populations, PCB-153 and *p*,*p*´-DDE were detected in at least 78% of subjects, and in 11 populations both compounds were detected in \> 95% of samples ([Table 2](#t2){ref-type="table"}). We replaced values below the limit of detection (LOD) or quantification (LOQ) by the LOD or LOQ divided by the square root of two ([@r29]).

We developed separate multiple linear regression models to estimate the association between birth weight and PCB-153 or *p*,*p*´-DDE concentrations in cord serum. Several known determinants of birth weight were included in the models regardless of actual degree of confounding of the POC--birth weight association in the individual cohorts ([@r3]; [@r19]). These included gestational age (weeks, linear and quadratic terms), offspring sex (male/female), region (cohort-specific categories), maternal body mass index (BMI; \< 18.5 kg/m², 18.5 ≤ 25 kg/m², 25 ≤ 30 kg/m², and ≥ 30 kg/m²), height (continuous), smoking status during pregnancy (non-smoking, smoking ≤ 9 cigarettes/day, smoking \> 9 cigarettes/day), socioeconomic status (cohort-specific categories), mother's age (\< 25 years, 25--29 years, 30--34 years, and ≥ 35 years), parity (0, 1, and ≥ 2), ethnicity (cohort-specific categories), and gestational age at time of sampling (first, second, and third trimester and postnatal). We evaluated sex and smoking status as potential effect modifiers based on literature regarding PCB exposure and growth or development ([@r24]; [@r67]), and we also examined interaction between PCB-153 and *p*,*p*´-DDE. Effect modification (interaction) was analyzed in models including main effects and cross-product terms. A *p*-value \< 0.05 for the effect of the cross-product was taken as an indication of interaction. Finally, we examined associations of gestational age with PCB-153 and *p*,*p*´-DDE in cord serum by linear regression to determine if associations with birth weight might be mediated by effects on gestational age.

We checked assumptions of normality, constancy of variance, independence (randomness), and linearity with informal diagnostic plots and formal tests \[White's General test for constancy of variance ([@r71]), Kolmogorov--Smirnov test for normality, and the lack of fit test for linearity ([@r47])\] and fitted regression models with and without influential outliers.

We used meta-analyses to estimate the overall summary effects of levels of PCB-153 and *p*,*p*´-DDE in cord serum on birth weight using R version 2.11.0 (R Foundation for Statistical Computing, Vienna, Austria). First, we tested for heterogeneity between effect estimates using the *Q*-test ([@r8]). If the result of the *Q*-test was statistically significant (*p* \< 0.05), an indication of heterogeneity across populations, we used random effects analyses ([@r12]). In addition, because the *Q*-test has low statistical power with few studies ([@r23]), we also used the *I*^2^ to assess heterogeneity ([@r26]). Following the thresholds provided by [@r11], we interpreted an *I*^2^ \> 30% as reflecting at least moderate heterogeneity. Therefore, when the *Q*-test was not statistically significant, but the *I*^2^ \> 30% we also used a random effects model. Using this approach we observed significant heterogeneity across study populations for the PCB-153 association (*p* = 0.01) and therefore we used a random effects model for all analyses. Summary estimates were weighted by the inverse variance of each cohort. To determine the influence of any particular population, we repeated the meta-analyses leaving one population out at the time.

Results
=======

The median birth weight ranged from 3,210 to 3,750 g, and median gestational age from 38 to 40 weeks. The proportion of cesarean sections was below 25% in all populations except RHEA (43.3%) \[see Supplemental Material, [Table 1](#t1){ref-type="table"} (<http://dx.doi.org/10.1289/ehp.1103767>)\]. In five populations, \> 20% of mothers were \< 25 years of age at delivery and in two populations \> 20% were \> 35 years of age. The proportion of nulliparous women exceeded 40% in nine of the populations.

The median concentration of PCB-153 in cord serum in the 15 study populations ranged from 20 to 484 ng/L \[[Table 2](#t2){ref-type="table"}; also see Supplemental Material, [Figure 1](#f1){ref-type="fig"} (<http://dx.doi.org/10.1289/ehp.1103767>)\]. The median cord serum PCB-153 concentration in the Faroese population was 3.4 times higher than the overall median of 140 ng/L. The populations with the lowest median PCB-153 concentrations in cord serum (e.g. Warsaw, Kharkiv, HUMIS, and RHEA) also had a narrow range of concentrations compared with the other populations (range from the 10th to the 90th percentiles: 7--83 ng/L compared with 14--1,302 ng/L).

![Adjusted regression coefficients (95% CI) of cord serum PCB-153 (ng/L) with birth weight (g). The squares are proportional to the inverse variance of the effect estimation of each cohort. Covariates included in the regression model: child's gestational age and sex, mother's region, maternal BMI, height, smoking status during pregnancy, socioeconomic status, mother's age, parity, and ethnicity, and time of sampling. Greenland, Warsaw, and Kharkiv are part of the INUENDO cohort.](ehp.1103767.g001){#f1}

The median level of *p*,*p*´-DDE in cord serum in the 15 populations ranged from 50 to 1,208 ng/L \[[Table 2](#t2){ref-type="table"}; also see Supplemental Material, [Figure 2](#f2){ref-type="fig"} (<http://dx.doi.org/10.1289/ehp.1103767>)\]. The median cord serum *p*,*p*´-DDE concentration in the Faroese population was 2.2 times higher than the overall median of 528 ng/L.

![Adjusted regression coefficients (95% CI) of cord serum *p*,*p*´-DDE (ng/L) with birth weight (g). The squares are proportional to the inverse variance of the effect estimation of each cohort. For model covariates, see Figure 1. Greenland, Warsaw, and Kharkiv are part of the INUENDO cohort.](ehp.1103767.g002){#f2}

Gestational ages ranged from 25--44 weeks \[see Supplemental Material, [Table 1](#t1){ref-type="table"} (<http://dx.doi.org/10.1289/ehp.1103767>)\]. Associations between POC concentrations and gestational age, including preterm births, were not statistically significant for any of the individual populations (data not shown) or in the meta-analysis \[for PCB-153: β = 6.2 × 10^--6^; 95% confidence interval (CI): --2.5 × 10^--5^, 3.7 × 10^--5^, *p* = 0.18; for *p*,*p*´-DDE: β = --1.2 × 10^--5^; 95% CI: --4.8 × 10^--5^, 2.5 × 10^--5^), *p* = 0.40\].

There was a statistically significant inverse association between PCB-153 concentrations in cord serum and birth weight in four populations (GRD, INMA cord, FLEHSI, and Greenland) ([Figure 1](#f1){ref-type="fig"}).

The meta-analysis showed a statistically significant inverse association between PCB-153 concentrations in cord serum and birth weight, corresponding to a 150-g (95% CI: --240, --50 g) reduction per 1-µg/L increase in cord serum PCB-153 ([Figure 1](#f1){ref-type="fig"}). A sensitivity analysis restricted to 3,856 nulliparous women produced a combined estimate of similar magnitude (β = --152 g/µg PCB-153; 95% CI: --341, 37, *p* = 0.12 \[see Supplemental Material, Table 3 (<http://dx.doi.org/10.1289/ehp.1103767>)\]. Analyses leaving out one population at the time did not show qualitatively different results from those reported (data not shown). In the meta-regression, biological sample matrix (cord serum, maternal blood/serum, or milk), time period (1990--1999/2000--2008), geographic area (FAROES2, FAROES3, Greenland, and HUMIS vs. other cohorts), and fish consumption (FAROES2, FAROES3, and Greenland) versus other cohorts were not significant predictors of heterogeneity among the study populations (data not shown). Separate meta-analytic regressions by sample matrix were consistent with the overall combined estimate for maternal serum (β = --120 g/µg PCB-143; 95% CI: --260, 10), stronger for the combined estimate for cord serum (β = --290 g/µg PCB-143; 95% CI: --540, --40) and weaker for breast milk (β = --50 g/µg PCB-143; 95% CI: --160, 50).

The meta-analysis of the relation between cord serum *p*,*p*´-DDE and birth weight ([Figure 2](#f2){ref-type="fig"}) did not indicate a statistically significant association (7-g reduction per 1-µg/L increase in cord serum *p*,*p*´-DDE; 95% CI: --18, 4). Analyses leaving one cohort out at a time did not show qualitatively different results. Separate meta-analytic regressions by sample matrix were consistent with the overall result and did not show an association between *p*,*p*´-DDE and birth weight (data not shown).

Associations of birth weight with PCB-153 and *p*,*p*´-DDE were not modified by sex or smoking (data not shown). Associations were also comparable when lipid-adjusted POC concentrations were modeled and when exposures were modeled using quadratic and log-linear transformation (data not shown). The expected associations between birth weight and sex (higher birth weight for males compared to females), tobacco smoking (smoking during pregnancy leading to lower birth weight) and body mass index (mothers with a high BMI have babies with higher birth weights) were demonstrated in all cohorts (data not shown). A sensitivity analysis restricted to infants born at term (e.g., gestational age between 37 and 42 weeks) showed no material changes in effect estimates (data not shown). When adjusting for *p*,*p*´-DDE in the models, the inverse association between PCB-153 and birth weight was not altered, and no significant interaction was found between PCB-153 and *p*,*p*´-DDE on birth weight within the cohorts (data not shown).

Discussion
==========

In our meta-analysis of 12 European birth cohorts (15 study populations) we observed decreases in birth weight independent of gestational age with increasing fetal PCB-153 concentrations. Across all cohorts birth weight declined by 150 g in association with a 1-µg/L increase of PCB-153 in cord serum---an exposure contrast that is close to the range of exposure levels across the cohorts. In magnitude, this association is comparable to the association between birth weight and smoking about 10 cigarettes per day during pregnancy, and more pronounced than the association with exposure to environmental tobacco smoking, which, according to a review of several earlier studies and meta-analyses, confers an average reduction in birth weight of 30--40 g ([@r37]). If the observed associations are causal, effects attributable to PCB exposure may be clinically relevant in the studied populations.

In contrast, we found no indications that fetal exposure to the DDT metabolite *p*,*p*´-DDE was related to birth weight, which is consistent with results of a large study based on the U.S. National Collaborative Perinatal Project (CPP) ([@r39]) that examined children born 1959--1966, before DDT was banned in the United States. Although results of the CPP study strongly suggested that DDT exposure was related to preterm birth and small for gestational age babies, no association was detected with maternal serum concentrations \< 10 µg/L (corresponding to a concentration of 2.5 µg/L in cord serum), which is higher than DDE concentrations in \> 95% of pregnant women participating in our study \[see Supplemental Material, [Figure 2](#f2){ref-type="fig"} (<http://dx.doi.org/10.1289/ehp.1103767>)\].

Fish is an important source of PCB exposure in communities with a high seafood intake ([@r61]), but fish meals also contribute substantially to internal PCB levels in other populations ([@r22]). Fatty fish contains n-3 polyunsaturated fatty acids (PUFA) that in a randomized controlled trial have been shown to prolong gestation and increase birth weight ([@r48]). A study of a representative sample of Danish pregnant women that explicitly addressed competitive effects of n-3 polyunsaturated fatty acids and organochlorine contaminants in seafood did not indicate that the effects on birth weight of the PUFA outweighed possible deleterious effects of PCBs or other contaminant exposures in the study population ([@r22]). Because the balance of effects is determined by the relative exposure levels, these findings may not apply to populations consuming other types of seafood. Other studies have not observed associations between PCBs and birth weight after adjusting for marine n-3 fatty acids ([@r20]). Accurate information on fish intake was not available in all cohorts. In general, we would expect residual confounding due to nondifferential misclassification of fish consumption to bias the association between PCBs and birth weight upward. Therefore, it seems unlikely that misclassification would cause the inverse association that we observed. In addition, fish consumption did not appear to contribute to heterogeneity across the cohorts. It is possible, however, that the misclassification might have been related to other sources of error and possibly to exposure, given that it varied among the cohorts such that any resulting bias might differ from expectations.

The PCB congener mixture in human tissues depends on the source of exposure and the time of sampling relative to exposure ([@r14]). Because PCB congeners vary in toxicity, differences in PCB congener profiles across populations may result in differences in effects on birth weight (if any) and explain some of the heterogeneity of the effect estimates. Although PCB-153 was highly correlated with the non-dioxin-like PCB-138 and PCB-180 in all cohorts (*r*-values ranging from 0.79 to 0.99), the association with the dioxin-like PCB-118 was weaker \[*r*-values ranging from 0.23 to 0.83 except in the Faroese \[*r* = 0.94 for FAROES2 and 0.90 for FAROES3, respectively ([@r21])\]. Other biopersistent organochlorines that are correlated with PCB-153, such as dioxins, hexachlorobenzene ([@r13]), hexachlorocyclohexane, dieldrin, and others ([@r38]) may add to the observed heterogeneity. It is not possible to examine possible differential effects of different mixtures of PCB congeners with the available data, but geographic area and calendar time of the study did not contribute to the observed heterogeneity.

Measurements from cord blood reflect exposure at delivery but may not be a good marker of exposure in early pregnancy ([@r45]), and maternal blood samples taken in late pregnancy (most samples in this study) may not truly reflect fetal exposure during embryogenesis. In a longitudinal study, [@r5] observed substantially lower serum concentrations of PCB congeners 6 weeks after delivery and in early pregnancy compared with the period before conception. The magnitude of change from early to late pregnancy (if any) is, to the best of our knowledge, unknown. Extrapolating fetal exposure from breast milk samples is less reliable, because exposure assessment is retrospective and exposure levels decline with time after delivery because of elimination through breast milk ([@r52]). On the other hand, results of a recent study suggest that while variable, the average monthly decrease in milk PCB is only 1% ([@r28]). Thus, the error in exposure introduced by using concentrations in milk one month after birth as a surrogate for prenatal exposure may be limited. We were not able to fully address the effects of different sampling times relative to pregnancy; but a poor proxy of a causal agent is more likely to result in dilution of risk estimates and therefore in particular is an issue in studies with no associations.

The conversion of concentrations measured from maternal serum and breast milk into those of cord serum was for descriptive purposes only, whereas the meta-analysis was based upon within-population regression estimates of exposures that were measured in a single biological matrix. We did not attempt to perform exposure--response analyses across the various populations, and thus did not include the absolute values of exposures in the meta-analysis.

The specificity of results indicating associations of birth weight with PCBs but not *p*,*p*´-DDE, as well as demonstration of the expected associations between birth weight and, respectively, infant sex and maternal tobacco smoking and BMI, supports the validity of findings and suggests that the association between PCB-153 and birth weight was not merely an artifact of study design or analysis. The correlation between concentrations of PCB-153 and *p*,*p*´-DDE was about 0.6 in most cohorts, but adjustment by *p*,*p*´-DDE in the individual cohorts did not attenuate the inverse association between PCB and birth weight, and there was no significant interaction between PCB-153 and *p*,*p*´-DDE on birth weight within or across cohorts.

Are results biased by reverse causation? Large maternal weight gain is correlated with high birth weight and could reduce POC levels because of dilution, thus producing an artificially negative association between POC concentration and birth weight. The much stronger association of PCB-153 than *p*,*p*´-DDE with birth weight is inconsistent with the dilution hypothesis, unless partitioning of PCBs into adipose tissue is greater than for DDE. But available data do not indicate that placental transfer of DDE deviates from PCBs in average ([@r46]). Moreover, in cohorts where data on weight gain during pregnancy were available \[INMA and PELAGIE (Perturbateurs endocriniens: Étude Longitudinale sur les Anomalies de la Grossesse, l'Infertilité et l'Enfance)\], additional analyses adjusting for weight gain during pregnancy did not change the risk estimates materially. For instance, for the INMA cord subcohort, the weight gain unadjusted risk estimate was --0.30 (95% CI: --0.57, --0.04) and the weight gain adjusted estimate was --0.31 (95% CI: --0.57, --0.05).

The discrepant findings in several earlier studies are puzzling ([@r10]; [@r15]; [@r17]; [@r20]; [@r33]; [@r38]; [@r43]; [@r45]; [@r50]; [@r56], [@r57], [@r55]; [@r59]; [@r66]; [@r74]). Among the populations included in this meta-analysis, only four showed a significant inverse association between PCB-153 and birth weight, of which one to two might be expected as chance findings at the 5% significance level (15 populations and 2 compounds = 30 comparisons). Reasons may be inadequate sample sizes, exposure misclassification, or exposure profile heterogeneity. However, we acknowledge that more consistent findings in earlier studies and across populations in this study would add to the credibility of the overall result.

Although the possible mode of action for effects of PCBs on birth weight is uncertain, the endocrine-disrupting properties of PCBs could be involved. Estrogens play a pivotal role in promoting fetal growth ([@r32]). Both estrogenic and anti-estrogenic activity has been observed for non-dioxin-like PCBs (NDL-PCBs). A recent study analyzing the toxicity profiles of 24 PCB congeners by *in vitro* assays revealed that higher chlorinated NDL-PCBs were weak estrogen receptor (ER) antagonists, and that several NDL-PCBs inhibited estradiol-sulfotransferase activity ([@r27]). Antiestrogenic congeners may inhibit fetal growth by their intrinsic activity or by disruption of endogenous estrogen metabolism. In addition, both estrogenic and antiestrogenic activity has been observed for hydroxylated metabolites of lower chlorinated non-dioxin-like PCBs ([@r9]), which are transferred more efficiently through placenta than the parent compounds ([@r49]). PCBs exhibit also a weak antiandrogenic activity, which may also have an impact on fetal growth ([@r42]). Finally, PCBs are also known to interfere with thyroid hormone status in animals and humans \[for reviews see [@r35] and [@r6]\]. *In vitro* assays showed that several NDL-PCBs inhibit estradiol-sulfotransferase activity and bound to transthyretin ([@r27]). It is well known that maternal hypothyroidism is related to low birth weight ([@r4]).

Low birth weight represents a mix of preterm delivery and reduced fetal growth. Because PCB levels were not associated with duration of gestation in either sex, our results suggest that PCB dose may be related to birth weight restriction rather than preterm delivery. This hypothesis was corroborated by an analysis restricted to infants born at term that showed no material changes in effect estimates, consistent with several recent studies ([@r22]; [@r24]; [@r39]; [@r59]).

In two studies, reduced birth weight has been observed in association with PCBs among boys only ([@r24]; [@r59]). This observation was not corroborated by our analyses. Earlier reports on sex-specific effects are not supported by animal or mechanistic evidence and may represent chance findings.

Conclusion
==========

Our harmonized meta-analysis of 12 European mother--child cohorts including \> 7,000 pregnancies suggests that low-level PCB exposure (or correlated exposures) impairs fetal growth, whereas current levels of *p*,*p*´-DDE were not associated with birth weight adjusted for gestational age. On average, birth weight declined by 150 g per 1-µg/L increase in PCB-153 cord serum concentration. The study adds to the mounting evidence that low-level exposure to PCBs is inversely associated with fetal growth.
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=====================
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[^1]: A full roster of the INMA Project Investigators can be found at <http://www.proyectoinma.org/presentacion->inma/listado-investigadores/en_listado-investigadores.html.
